Merck KGaA testing cancer vaccine.
Bloomberg News (11/4, Kresge) reports that "Merck KGaA of Germany is gambling an unproven therapy that spurs the immune system to attack cancer cells will increase its share of a $48 billion oncology market." The company "is enrolling more than 900 women globally in an experiment of a so-called cancer vaccine to treat breast tumors even before having evidence from smaller studies that the product works." The drugmaker "plans to seek approval for the treatment, known as Stimuvax [BLP25 liposome vaccine], for lung cancer in 2012 based on studies in that disease begun in 2007, said Wolfgang Wein, head of the company's oncology business."
© 2009 Breastcancer.org. All rights reserved.